1. Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN. (13th December 2013) Authors: Gandhi, Anita K.; Kang, Jian; Havens, Courtney G.; Conklin, Thomas; Ning, Yuhong; Wu, Lei; Ito, Takumi; Ando, Hideki; Waldman, Michelle F.; Thakurta, Anjan; Klippel, Anke; Handa, Hiroshi; Daniel, Thomas O.; Schafer, Peter H.; Chopra, Rajesh Journal: British journal of haematology Issue: Volume 164:Number 6(2014:Mar.) Page Start: 811 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma. (23rd February 2016) Authors: Rychak, Emily; Mendy, Derek; Shi, Tao; Ning, Yuhong; Leisten, Jim; Lu, Ling; Miller, Karen; Narla, Rama K.; Orlowski, Robert Z.; Raymon, Heather K.; Bjorklund, Chad C.; Thakurta, Anjan; Gandhi, Anita K.; Cathers, Brian E.; Chopra, Rajesh; Daniel, Thomas O.; Lopez‐Girona, Antonia Journal: British journal of haematology Issue: Volume 172:Number 6(2016) Page Start: 889 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗